302 related articles for article (PubMed ID: 30565428)
1. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
[TBL] [Abstract][Full Text] [Related]
2. MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression.
Yan J; Jiang JY; Meng XN; Xiu YL; Zong ZH
J Exp Clin Cancer Res; 2016 Feb; 35():31. PubMed ID: 26872615
[TBL] [Abstract][Full Text] [Related]
3. SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer.
Xu Y; Miao C; Jin C; Qiu C; Li Y; Sun X; Gao M; Lu N; Kong B
Exp Cell Res; 2018 Feb; 363(2):160-170. PubMed ID: 29305171
[TBL] [Abstract][Full Text] [Related]
4. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
[TBL] [Abstract][Full Text] [Related]
5. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract][Full Text] [Related]
6. HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling.
Khella CA; Franciosa L; Rodirguez-Rodriguez L; Rajkarnikar R; Mythreye K; Gatza ML
Mol Cancer Res; 2023 Oct; 21(10):1037-1049. PubMed ID: 37342066
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-488 inhibits ovarian cancer cell metastasis through regulating CCNG1 and p53 expression.
Guo JY; Wang XQ; Sun LF
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2902-2910. PubMed ID: 32271408
[TBL] [Abstract][Full Text] [Related]
8. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
[TBL] [Abstract][Full Text] [Related]
9. Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer.
Wu H; Li R; Zhang Z; Jiang H; Ma H; Yuan C; Sun C; Li Y; Kong B
J Ovarian Res; 2019 Dec; 12(1):125. PubMed ID: 31884974
[TBL] [Abstract][Full Text] [Related]
10. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
11. Long non‑coding RNA OIP5‑AS1 facilitates the progression of ovarian cancer via the miR‑128‑3p/CCNG1 axis.
Liu Y; Fu X; Wang X; Liu Y; Song X
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760168
[TBL] [Abstract][Full Text] [Related]
12. The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer.
Shang Y; Feng B; Zhou L; Ren G; Zhang Z; Fan X; Sun Y; Luo G; Liang J; Wu K; Nie Y; Fan D
Oncotarget; 2016 Jan; 7(1):538-49. PubMed ID: 26623719
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
Kreuzinger C; von der Decken I; Wolf A; Gamperl M; Koller J; Karacs J; Pfaffinger S; Bartl T; Reinthaller A; Grimm C; Singer CF; Braicu EI; Cunnea P; Gourley C; Smeets D; Boeckx B; Lambrechts D; Perco P; Horvat R; Berns EMJJ; Cacsire Castillo-Tong D
Cancer Lett; 2019 Sep; 459():1-12. PubMed ID: 31150822
[TBL] [Abstract][Full Text] [Related]
14. Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
Price JC; Azizi E; Naiche LA; Parvani JG; Shukla P; Kim S; Slack-Davis JK; Pe'er D; Kitajewski JK
PLoS One; 2020; 15(6):e0233962. PubMed ID: 32525899
[TBL] [Abstract][Full Text] [Related]
15. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
17. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
[TBL] [Abstract][Full Text] [Related]
18. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
19. p53 protein aggregation promotes platinum resistance in ovarian cancer.
Yang-Hartwich Y; Soteras MG; Lin ZP; Holmberg J; Sumi N; Craveiro V; Liang M; Romanoff E; Bingham J; Garofalo F; Alvero A; Mor G
Oncogene; 2015 Jul; 34(27):3605-16. PubMed ID: 25263447
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
